oxidopamine has been researched along with a-Synucleinopathies in 2 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Singh, A | 1 |
| Panhelainen, A | 1 |
| Voutilainen, MH | 1 |
| Shrigley, S | 1 |
| Nilsson, F | 1 |
| Mattsson, B | 1 |
| Fiorenzano, A | 1 |
| Mudannayake, J | 1 |
| Bruzelius, A | 1 |
| Ottosson, DR | 1 |
| Björklund, A | 1 |
| Hoban, DB | 1 |
| Parmar, M | 1 |
2 other studies available for oxidopamine and a-Synucleinopathies
| Article | Year |
|---|---|
Feasibility of combining alpha-synuclein aggregation and 6-OHDA in embryonic midbrain culture for modeling dopamine neuron degeneration.
Topics: alpha-Synuclein; Animals; Dopamine; Feasibility Studies; Mesencephalon; Mice; Nerve Degeneration; Ox | 2023 |
Grafts Derived from an α-Synuclein Triplication Patient Mediate Functional Recovery but Develop Disease-Associated Pathology in the 6-OHDA Model of Parkinson's Disease.
Topics: alpha-Synuclein; Animals; Dopaminergic Neurons; Humans; Induced Pluripotent Stem Cells; Oxidopamine; | 2021 |